Drug development is emerging as a rapidly growing application area in the immunoassay market, driven by innovations in drug discovery and increasing need for efficient testing methodologies. The integration of immunoassays in clinical trials is vital, enhancing reliability and speed of therapeutic assessments. For detailed analysis of this emerging application, consult the Immunoassay Market report.
Preclinical and Clinical Applications
Immunoassays support drug development at multiple stages—target identification and validation, lead optimization, pharmacokinetic/pharmacodynamic studies, biomarker analysis, and immunogenicity assessment. Their sensitivity and specificity enable precise measurement of drug concentrations and biological responses.
The drug development application is anticipated to grow from USD 6.0 billion in 2024 to USD 9.0 billion by 2035, reflecting heightened investment in pharmaceuticals and biotechnologies seeking efficiency in drug discovery processes.
Biomarker Analysis
Drug development increasingly relies on biomarkers for patient stratification, treatment response monitoring, and surrogate endpoint assessment. Immunoassays provide reliable biomarker measurements essential for these applications.
Biosimilar Development
Growing biosimilar development creates demand for immunoassays demonstrating comparability between biosimilar and reference products. Sensitive assays detecting subtle differences are essential for regulatory approval.
Regulatory Acceptance
Regulatory agencies accept well-validated immunoassay data for drug approval submissions, encouraging pharmaceutical companies to invest in robust assay development and validation.
Growth Drivers
Heightened investment in pharmaceuticals and biotechnologies seeking efficiency in drug discovery processes drives rapid growth of immunoassay applications in drug development.
